Literature DB >> 8738797

Acute renal failure and the MELAS syndrome, a mitochondrial encephalomyopathy.

F Hsieh1, R Gohh, L Dworkin.   

Abstract

Melas (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) is one of a group of heterogeneous yet clinically distinct syndromes ascribed to a defect in mitochondrial function. Here, the case of a patient diagnosed with the MELAS syndrome who subsequently developed acute renal failure is reported. Although no clear renal insult was evident at the time, the clinical picture was consistent with the diagnosis of acute tubular necrosis. The patient's renal function subsequently returned to baseline. This article reviews the literature concerning renal involvement in the mitochondrial encephalomyopathies, including MELAS, and proposes a mechanism by which patients suffering from mitochondrial disorders may be more susceptible to renal hypoxic injury and acute renal failure.

Entities:  

Mesh:

Year:  1996        PMID: 8738797     DOI: 10.1681/ASN.V75647

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  4 in total

1.  Melas syndrome.

Authors:  S K Singh; D Sarin; J M Puliyel; R Srivastav; R Gupta; N Kumar; A Mathews
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

2.  Recurrent episodic acute kidney injury as presenting manifestation of mitochondrial myopathy.

Authors:  T P Matthai; U G Zachariah; S M Matthai
Journal:  Indian J Nephrol       Date:  2014-11

3.  A boy with mitochondrial disease: asymptomatic proteinuria without neuromyopathy.

Authors:  Yuka Ueda; Atsushi Ando; Taeko Nagata; Hidehiko Yanagida; Kazuro Yagi; Keisuke Sugimoto; Mitsuru Okada; Tsukasa Takemura
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

4.  A MELAS Patient Developing Fatal Acute Renal Failure with Lactic Acidosis and Rhabdomyolysis.

Authors:  Hisashi Ito; Shigeru Fukutake; Sanae Odake; Riki Okeda; Osamu Tokunaga; Tetsumasa Kamei
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.